Supportive care for women with gynecologic cancers

Expert Review of Anticancer Therapy

Volumn 8, Issue 2, 2008, Pages 227-241

  Chase, Dana M ^a   Monk, Bradley J ^a   Wenzel, Lari B ^a   Tewari, Krishnansu S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gynecologic oncology; Quality of life; Supportive care

Indexed keywords

AMIFOSTINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CANNABIS; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; ENSURE; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN; ICOSAPENTAENOIC ACID; LORAZEPAM; MEGESTROL ACETATE; MORPHINE SULFATE; NAPROXEN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OPIATE; OXYCODONE; PARACETAMOL; PARENTERAL SOLUTION; PERCOCET; PERCODAN; RECOMBINANT ERYTHROPOIETIN; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ADD ON THERAPY; AGE DISTRIBUTION; ALTERNATIVE MEDICINE; ANEMIA; ANXIETY DISORDER; ASCITES; CACHEXIA; CANCER PAIN; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DRUG HYPERSENSITIVITY; FEMALE; FEVER; GYNECOLOGIC CANCER; GYNECOLOGIC CARE; HEALTH CARE NEED; HOME OXYGEN THERAPY; HUMAN; HYPOTENSION; LYMPHEDEMA; METABOLIC DISORDER; MORBIDITY; MOTOR NEUROPATHY; NAUSEA; NEUROPATHIC PAIN; NUTRITIONAL SUPPORT; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SEXUAL DYSFUNCTION; SMALL INTESTINE OBSTRUCTION; UNSPECIFIED SIDE EFFECT; VOMITING;

COMBINED MODALITY THERAPY; EMPATHY; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SOCIAL SUPPORT; WOMEN'S HEALTH;

EID: 40749157834     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.2.227     Document Type: Review

References (89)

1. Le T, Leis A, Pahwa P et al. Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet. Gynecol. Surv. 58(11), 749-758 (2003).
2. Monk BJ, Wenzel L. Palliative care and quality of life. In: Clinical Gynecologic Oncology (7th Edition). DiSaia PJ, Creasman WT (Eds). Elsevier, Inc., St Louis, MO, USA (2007).
3. Aranda S, Yates P, Edwards H et al. Barriers to effective cancer pain management: a survey of Australian family caregivers. Eur. J. Cancer Care (Engl.) 13(4), 336-343 (2004).
4. Vaz AF, Pinto-Neto AM, Conde DM et al. Quality of life of women with gynecologic cancer: associated factors. Arch. Gynecol. Obstet. 276(6), 583-589 (2007).
5. Silver J, Mayer RS. Barriers to pain management in the rehabilitation of the surgical oncology patient. J. Surg. Oncol. 95(5), 427-435 (2007).
6. Burton AW, Fanciullo GJ, Beasley RD et al. Chronic pain in the cancer survivor: a new frontier. Pain Med. 8(2), 189-198 (2007).
7. Goldberg GR, Morrison RS. Pain management in hospitalized cancer patients: a systematic review. J. Clin. Oncol. 25(13), 1792-1801 (2007).
8. Bajwa ZH, Warfield CA. Overview of cancer pain. In: UpToDate. Rose BD (Ed.). UpToDate, Waltham, MA, USA (2007).
9. Chang HM. Cancer pain management. Med. Clin. North Am. 83(3), vii711-vii736 (1999).
10. Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol. Oncol. Clin. North Am. 16(3), 527-541 (2002).
11. Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 19(3), 179-187 (2005).
12. Marin Caro MM, Laviano A, Pichard C. Impact of nutrition on quality of lifi during cancer. Curr. Opin. Clin. Nutr. Metab. Care 10(4), 480-487 (2007).
13. Samoso JT, Canada T, Larson B et al. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet. Gynecol. 95(6 Pt 1), 844--846 (2000).
14. Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin. Nutr. 25(5), 711-715 (2006).
15. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2)18, CD004310 (2005).
16. Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J. Am. Med. Dir. Assoc. 4(5), 255-256 (2003).
17. Brown D, Roberts JA, Elkins TE et al. Hard choices: the gynecologic cancer patient's end-of-life pteferences. Gynecol. Oncol. 55(3 Pt 1), 355-362 (1994).
18. Bozzetti F, Cozzaglio L, Biganzoli E et al. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin. Nutr. 21(4), 281-288 (2002).
19. Brard L, Weitzen S, Strubel-Lagan SL et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol. Oncol. 103(1), 176-180 (2006).
20. Ripamond C. Management of dyspnea in advanced cancer patients. Support. Care Cancer 7(4), 233-243 (1999).
21. Easson AM, Bezjak A, Ross S et al. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Am. Surg. Oncol. 14(8), 2348-2357 (2007).
22. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin. Oncol. 15(2), 59-72 (2003).
23. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur. J. Cancer 42(5), 589-597 (2006).
24. Burges A, Wimberger P, Kümper C et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional and-EpCAM × anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res. 13(13), 3899-3905 (2007).
25. Mangili G, Aletti G, Frigerio L et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int. J. Gynecol. Cancer 15(5), 830-835 (2005)
26. Krebs HB, Goplerud DR. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet. Gynecol. 61(3), 327-330 (1983).
27. Pothuri B, Meyer L, Gerardi M et al. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol. Oncol. 95(1), 193-195 (2004).
28. Bryan DN, Radbod R, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int. J. Gynecol. Cancer 16(1), 125-134 (2006).
29. Moretti R, Pizzi B, Colizza MT et al. Symptom management in a patient with end-stage ovarian cancer. case report. Eur. J. Gynaecol. Oncol. 28(4), 325-327 (2007).
30. Rodriguez AO, Wun T, Chew H et al. Venous thromboembolism in ovarian cancer. Gynecol. Oncol. 105(3), 784-790 (2007).
31. Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol. Oncol. 105(3), 813-819 (2007).
32. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support. Care Cancer 13(11), 870-877 (2005).
33. Slatkin N. Cancer-related pain and its pharmacologic management in the patient with bone mctastasis. J. Support. Oncol. 4(2 Suppl. 1), 15-21 (2006).
34. Sun CC, Bodurka DC, Donato ML et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol. Oncol. 87(1), 118-128 (2002).
35. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J. Support. Oncol. 5(2 Suppl. 1), 5-12 (2007).
36. Schwartzberg LS. Chemotherapy-induoed nausea and vomiting. which antiemetic for which therapy? Oncology 21(8), 946-953; discussion 954, 959, 962 passim (2007).
37. Tipton JM, McDaniel RW, Barbour L et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin. J. Oncol. Nurs. 11(1), 69-78 (2007).
38. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol. 24(18), 2932-2947 (2006).
39. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J. Support. Oncol. 5(5 Suppl. 3), 1-9 (2007).
40. Tramèr MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br. Med. J. 323(7303), 16-21 (2001).
41. Smith GF, Toonen TR. Primary care of die patient with cancer. Am. Fam. Physician 75(8), 1207-1214 (2007).
42. Donovan HS, Ward S. Representations of fatigue in women receiving chemotherapy for gynecologic cancers. Oncol. Nurs. Forum 32(1), 113-116 (2005).
43. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl. 5), 31-40 (2004).
44. Barrett-Lee P, Bokemeyer C, Gascón P et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 10(9), 743-757 (2005).
45. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?' Oncologist 9(Suppl. 5), 31-40 (2004).
46. Vaupel P, Thews 0, Mayer A et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strablenther. Onkol. 178(12), 727-731 (2002).
47. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of CJinical Oncology and the American Society of Hematology. J. Clin. Oncol. 20(19), 4083-4107 (2002).
48. Kurz CH, Marth CH, Windbichler G et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol. Oncol. 65(3), 461-466 (1997).
49. Heddens D, Alberts DS, Hannigan EV et al. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol. Oncol. 86(3), 239-243 (2002).
50. Hensley ML, Lebeau D, Leon LF et al. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol. Oncol. 81(3), 485-489 (2001).
51. Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann. Pharmacother. 40(1), 58-65; quiz 169 (2006).
52. Dc Los Santos JF, Thomas GM. Anemia correction in malignancy management: threat or opportunity? Gynecol. Oncol. 105(2), 517-529 (2007).
53. Huang HQ, Brady MF, Cella D et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int. J. Gynecol. Cancer 17(2), 387-393 (2007).
54. Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovariancancer (MITO-4) retrospective study. BMC Cancer 6, 5 (2006).
55. Cavaletti G, Bogliun G, Marzorati L et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol. 15(9), 1439-1442 (2004).
56. Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol. Oncol. Clin. North Am. 16(3), 527-541 (2002).
57. Albers J, Chaudhry V, Cavaletti G et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. (1) (2007).
58. Hilpert F, Stähle A, Torné O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized Phase II study from the Arbeitsgemeinschaft Gynäikologische Onkologoie (AGO) Ovarian Cancer Study Group. Support. Care Cancer 13(10), 797-805 (2005).
59. Argyriou AA, Chroni E, Koutras A et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support. Care Cancer 14(11), 1134-1140 (2006).
60. Stead ML, Fallowfield L, Selby P et al. Psychosexual function and impact of gynaecological cancer. Baillière's best practice & research. Clin. Obstet. Gynaecol. 21(2), 309-320 (2007).
61. Brotto LA, Heiman JR, Goff B et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch. Sex. Behav. (2007) (Epub ahead of print).
62. Hopkins ML, Fung MF, Le T et al. Ovarian cancer patients and hormone replacement therapy. a systematic review. Gynecol. Oncol. 92(3), 827-832 (2004).
63. Barakat RR, Bundy BN, Spirtos NM et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 24(4), 587-592 (2006).
64. Ell K, Sanchez K, Vourlekis B et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J. Clin. Oncol. 23(13), 3052-3060 (2005).
65. Fowler JM, Carpenter EM, Gupta P et al. The gynecologic oncology consult: symptom presentation and concurrent symptoms of depression and anxiety. Obstet. Gynecol. 103(6), 1211-1217 (2004).
66. Chan YM, Ngan HY, Yip PS et al. Psychosocial adjustment in gynecologic cancer survivors: a longitudinal study on risk factors for maladjustment. Gynecol. Oncol. 80(3), 387-394 (2001).
67. Bodurka-Bevers D, Basen-Engquist K, Carmack CL et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol. Oncol. 78(3 Pt 1), 302-308 (2000).
68. Rodin G, Lloyd N, Katz M et al. The treatment of depression in cancer patients: a systematic review. Support. Care Cancer 15(2), 123-136 (2007).
69. Rodin G, Lloyd N, Katz M et al. The treatment of depression in cancer patients: a systematic review. Support. Care Cancer 15(2), 123-136 (2007).
70. Lutgendorf SK, Anderson B, Ullrich P et al. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer 94(1), 131-140 (2002).
71. Beesley V, Janda M, Eakin E et al. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 109(12), 2607-2614 (2007).
72. Kligman L, Wong RK, Johnston M et al. The treatment of lymphedema related to breast cancer: a systematic review and evidence summary. Support. Care Cancer 12(6), 421-431 (2004).
73. Modesitt SC, van Nagell JR. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet. Gynecol. Surv. 60(10), 683-692 (2005).
74. Ben-Ami I, Vaknin Z, Schneider D et al. Perioperative morbidity and mortality of gynecological oncologic surgery in elderly women. Int. J. Gynecol. Cancer 16(1), 452-457 (2006).
75. Gridelli C. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. Drugs Aging 21(13), 825-832 (2004).
76. Swisher EM, Cohn DE, Goff BA et al. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol. Oncol. 84(3), 363-367 (2002).
77. von Gruenigen VE, Frasure HE, Jenison EL et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol. Oncol. 103(1), 120-126 (2006).
78. Thorsen L, Skovlund E, Strømme SB et al. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J. Clin. Oncol. 23(10), 2378-2388 (2005).
79. Karvinen KH, Courneya KS, Campbell KL et al. Exercise preferences of endometrial cancer survivors: a population-based study. Cancer Nurs. 29(4), 259-265 (2006).
80. Courneya KS, Karvinen KH, Campbell KL et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol. Oncol. 97(2), 422-430 (2005).
81. Miller BE, Pittman B, Strong C. Gynecologic cancer patients' psychosocial needs and their views on the physician's role in meeting those needs. Int. J. Gynecol. Cancer 13(2), 111-119 (2003).
82. Hodgkinson K, Butow P, Fuchs A et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol. Oncol. 104(2), 381-389 (2007).
83. Wenzel LB, Huang HQ, Armstrong DK et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(4), 437-443 (2007).
84. Wenzel L, Huang HQ, Monk BJ et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 23(24), 5605-5612 (2005).
85. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am. Fam. Physician 74(8), 1347-1354 (2006).
86. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov. Today 12(19-20), 794-805 (2007).
87. Argyriou AA. Chroni E, Koutras A et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64(1), 26-31 (2005).
88. Wang J, Lu Z, An JL. Protection against chemotherapy-induced alopecia. Pharm. Res. 23(11), 2505-2514 (2006).
89. Hurria A, Somlo G, Ahles T. Renaming "chemobrain". Cancer Invest. 25(6), 373-377 (2007).